Project Details
Description
HM2023-05: GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE??) for the Treatment of High Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML
| Status | Active |
|---|---|
| Effective start/end date | 11/18/24 → 10/31/33 |
Funding
- GT BIOPHARMA, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.